NEUROENDOCRINOLOGY is a prestigious interdisciplinary journal published by KARGER, serving the vibrant fields of cellular and molecular neuroscience, endocrine systems, and metabolism. With an ISSN of 0028-3835 and an E-ISSN of 1423-0194, this journal stands at the forefront of neuroendocrinology research, boasting an impactful position in the academic community, as highlighted by its 2023 Scopus rankings placing it in the top quartiles across multiple relevant categories. Since its inception in 1965, NEUROENDOCRINOLOGY has consistently contributed to the advancement of knowledge and understanding in the interplay between the nervous system and endocrine functions. Although it does not currently offer Open Access, the journal aims to disseminate groundbreaking studies, reviews, and clinical insights that address critical issues in neuroendocrine interactions. With its headquarters in Basel, Switzerland, NEUROENDOCRINOLOGY remains a vital resource for researchers, professionals, and students eager to explore the complexities of neuroendocrine dynamics and their implications for health and disease.

EXPERIMENTAL NEUROLOGY is a premier academic journal published by Academic Press Inc, Elsevier Science, focusing on advancements in the fields of Developmental Neuroscience and Neurology. With an impressive Impact Factor and ranked in the Q1 quartile of both categories—positioning it among the top-tier journals—this publication has established itself as a vital resource for researchers, clinicians, and students alike. Since its inception in 1959, it has fostered the dissemination of cutting-edge research and innovative approaches to understanding neurological function and related disorders. While EXPERIMENTAL NEUROLOGY currently operates under a subscription access model, its rich archives and ongoing contributions to the field continue to inspire and inform the next generation of neurobiologists. The journal also boasts a high ranking in Scopus, placing fourth in Developmental Neuroscience and twentieth in Neurology, indicating its robust influence and scholarly significance. For those committed to advancing knowledge in these critical areas, EXPERIMENTAL NEUROLOGY is an indispensable platform for inquiry and discovery.

GLIA is a premier journal in the fields of Cellular and Molecular Neuroscience and Neurology, published by WILEY. With an impressive track record since its inception in 1988, GLIA has become an essential resource for researchers and professionals interested in the complexities of glial cells and their roles in the nervous system. Featuring articles that encompass a wide range of topics, from basic research to clinical implications, the journal is committed to advancing our understanding of neurological functions and disorders. Although not an open access publication, GLIA maintains its reputation with a significant impact factor, consistently ranking in the Q1 category as noted in 2023 Scopus rankings. With its comprehensive scope and high-quality peer-reviewed content, GLIA serves as a vital platform for disseminating groundbreaking research in the ever-evolving landscape of neuroscience.

Retrovirology is a prominent open-access journal published by BMC since 2004, dedicated to the field of retroviral research. With a strong focus on advancing knowledge in both infectious diseases and virology, this interdisciplinary journal has achieved a commendable ranking of Q2 in its respective categories as of 2023, reflecting its significant contribution to the scientific community. Hosted in the United Kingdom, Retrovirology serves a global audience of researchers, professionals, and students, making vital research accessible to all without barriers. The journal's emphasis on high-quality peer-reviewed articles supports the dissemination of groundbreaking findings that could shape the future of virology and related fields. With an impressive Scopus ranking, including a percentile of 65th in Medicine: Infectious Diseases, it stands out as a valuable resource for those committed to understanding and combating viral diseases. Retrovirology continues to be an essential platform for innovative research, with its open-access model ensuring that transformational science reaches the widest possible audience.

Fluids and Barriers of the CNS is a premier open-access journal published by BMC, dedicated to advancing the field of neuroscience by exploring the complexities of the fluid dynamics and barriers of the central nervous system. Since its inception in 2011, the journal has established itself as a vital resource for researchers, professionals, and students alike, providing a platform for innovative research and critical discussions in areas such as cellular and molecular neuroscience, developmental neuroscience, neurology, and miscellaneous medicine. With an impressive Q1 ranking across multiple categories in 2023, and strong performance metrics such as being ranked in the 93rd percentile in Developmental Neuroscience, this journal not only highlights cutting-edge research but also contributes to the ongoing dialogue surrounding neurophysiology and pathology. As an open-access journal based in London, United Kingdom, it ensures that high-quality research is accessible to a global audience, fostering collaboration and knowledge-sharing in the neuroscientific community.

EXERCISE IMMUNOLOGY REVIEW, published by W W F VERLAGSGESELLSCHAFT GMBH, stands as a premier journal within the realms of Immunology, Medicine, and Sports Science. With an impressive Q1 ranking in these fields as of 2023, it is recognized for its significant contributions to understanding the interplay between physical activity and immune function. The journal, which has been publishing since 1996 and continues to evolve through 2024, serves as an essential resource for researchers, professionals, and students eager to explore cutting-edge findings and discussions. Although it is not an open access publication, its content is accessible through institutional subscriptions and individual purchases, ensuring its reach across a global audience. As the journal consistently ranks in the 96th percentile in General Medicine on Scopus, it underscores its vital role in advancing the dialogue on how exercise influences health and disease management.

The INTERNATIONAL JOURNAL OF NEUROSCIENCE, published by TAYLOR & FRANCIS LTD, stands as a vital resource in the field of neuroscience since its inception. With a proud history of publication from 1970 to 2024, this journal is committed to advancing knowledge in various domains of neuroscience, from fundamental research to clinical applications. It is indexed with an ISSN of 0020-7454 and an E-ISSN of 1563-5279, reflecting its wide reach and recognition. The journal maintains a respectable position in the academic landscape, categorized as Q2 in Medicine (miscellaneous) and Q3 in Neuroscience (miscellaneous) as of 2023, signifying its relevance among researchers and professionals. Although it currently does not offer open access, the journal remains a significant platform for disseminating groundbreaking research, thereby fostering collaboration and innovation within the neuroscience community. Located in the United Kingdom, the journal aims to bridge gaps in neuroscience knowledge, making it an essential reading for students, professionals, and researchers dedicated to unraveling the complexities of the nervous system.

Neurology-Neuroimmunology & Neuroinflammation, published by LIPPINCOTT WILLIAMS & WILKINS, stands at the forefront of research in the rapidly evolving fields of neurology and neuroimmunology. Since its inception in 2014, this prestigious journal has embraced an Open Access model, ensuring that groundbreaking findings are readily available to researchers, clinicians, and students worldwide. Covering a broad spectrum of topics related to neuroinflammation, the journal has gained a remarkable reputation, attaining a Q1 ranking in both Neurology and Neurology (clinical) as of 2023, and ranking #6 out of 192 in the neuroscience category on Scopus. The journal's commitment to high-quality research aims to facilitate the understanding of neurological disorders, promote innovative therapies, and inspire collaboration among professionals. Addressing critical issues at the intersection of neurology, immunology, and clinical practice, Neurology-Neuroimmunology & Neuroinflammation is an essential platform for the dissemination of knowledge and the advancement of this vital field.

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, published by Wiley, is a prestigious peer-reviewed journal dedicated to advancing the understanding of the peripheral nervous system. With an ISSN of 1085-9489 and E-ISSN of 1529-8027, this journal has been a vital resource for researchers and clinicians since its inception in 1996 and continues to publish cutting-edge research through to 2024. Ranked in the second quartile (Q2) in both Medicine (miscellaneous) and Neurology (clinical), and holding a commendable position in the third quartile (Q3) for Neuroscience (miscellaneous), it reflects a strong impact factor within its fields, including a 72nd percentile rank in clinical neurology. The journal focuses on providing a platform for innovative research findings, reviews, and clinical studies that broaden the understanding of peripheral nerve pathophysiology and therapies. Researchers, students, and professionals in neuroscience and related disciplines will find the journal's diverse range of articles invaluable for keeping abreast of the latest developments and fostering scientific dialogue.

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.